The right dose depends on the indication, the patients weight and health history, and the prescribing providers clinical judgment
Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, et al
The proposed LNP-mRNA therapy eliminated overactivated fibroblasts to rescue pulmonary fibrosis
Using co-immunoprecipitation (CO-IP), the study confirmed that FOXO4-DRI prevents FOXO4 binding to p53, facilitating phosphorylated p53 nuclear exclusion, which triggers BAX upregulation and cleaved caspase-3 activation driving selective apoptosis of senescent endothelial cells
identity confirmed by standard analytical methods) Packaging Format : 20 mg lyophilized (freezedried) powder in a sealed researchuse vial Storage Conditions : Store at 28 C ( 20 C for long-term storage)